Australia’s Drug Patent Clock: The Real Timeline Behind “Protection” (and Why It Rarely Matches the Headlines)
If you’ve ever heard that a drug is “protected until 2032” (or “won’t face generic competition until 2028”), you’ve probably been handed a si…

Pharma doesn’t always need a brand-new drug to extend its profits.
Sometimes it just needs a new version—and a legal pathway that lets it re-enter the patent landscape without starting from scratch.
That’s the core idea behind the “reformulation playbo…

Drug spend is not a mystery problem—it’s a timing problem.
If your organization is still negotiating drug prices without a clear view of when exclusivity ends, you’re not managing cost—you’re guessing. And in today’s market, guessing can be the diffe…

The “Drug Patent Cliff” Isn’t a Finance Problem—It’s a Procurement Problem.
If you’re a procurement leader, you’ve probably felt it: the sudden scramble when a key brand’s exclusivity ends, the frantic vendor calls, the “can we switch?” emails, the int…

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical trials are supposed to be about evidence—patient outcomes, endpoints, safety signals, and regulatory clarity. But there’s a quieter risk growing …

The “Hard 20-Year Limit” in New Zealand Isn’t Just a Legal Detail—it’s the Clock That Decides Who Wins.
In drug development, timelines are everything. But in New Zealand, one particular timeline—an unusually rigid “hard 20-year limit”—quietly shapes al…

Most people in pharma think they understand “patent dates.” They don’t.
If you work in drug development, regulatory strategy, or commercial planning, you’ve probably seen it: a spreadsheet with a clean-looking “patent expiry” date—followed by a scram…

Pharma has a patent problem—and a tax problem.
For years, the industry has treated IP strategy like a pure play offense: file early, extend late, defend aggressively, monetize relentlessly. But the modern reality is that the “value” of a patent isn’t j…

The 180-Day Clock Is Not a Deadline—It’s a Battlefield.
Generic drug launches live and die by timing, but few timelines are as consequential—or as misunderstood—as the 180-day exclusivity period under the Hatch-Waxman framework. In theory, it’s a cle…

Europe’s “Divisional Patent Trap”: How Big Pharma Can Delay Generics Without Losing in Court
If you’ve ever wondered how a company can keep generics off the shelf for years—despite losing key legal battles—this is the mechanism.
Europe’s patent system …